These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35331006)

  • 1. Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys.
    Tukov FF; Mansfield K; Milton M; Meseck E; Penraat K; Chand D; Hartmann A
    Hum Gene Ther; 2022 Jul; 33(13-14):740-756. PubMed ID: 35331006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
    Finkel RS; Darras BT; Mendell JR; Day JW; Kuntz NL; Connolly AM; Zaidman CM; Crawford TO; Butterfield RJ; Shieh PB; Tennekoon G; Brandsema JF; Iannaccone ST; Shoffner J; Kavanagh S; Macek TA; Tauscher-Wisniewski S
    J Neuromuscul Dis; 2023; 10(3):389-404. PubMed ID: 36911944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
    Day JW; Mendell JR; Mercuri E; Finkel RS; Strauss KA; Kleyn A; Tauscher-Wisniewski S; Tukov FF; Reyna SP; Chand DH
    Drug Saf; 2021 Oct; 44(10):1109-1119. PubMed ID: 34383289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
    Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
    Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
    Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery.
    Hudry E; Aihara F; Meseck E; Mansfield K; McElroy C; Chand D; Tukov FF; Penraat K
    Mol Ther; 2023 Oct; 31(10):2999-3014. PubMed ID: 37515322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy.
    Blair HA
    CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].
    Atsumi A; Yoneda T; Tsuchida K; Kagawa Y; Tominaga S; Kawase K; Kikuchi N
    Nihon Yakurigaku Zasshi; 2022; 157(1):53-61. PubMed ID: 34980814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy.
    René CA; Parks RJ
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology.
    Hordeaux J; Buza EL; Dyer C; Goode T; Mitchell TW; Richman L; Denton N; Hinderer C; Katz N; Schmid R; Miller R; Choudhury GR; Horiuchi M; Nambiar K; Yan H; Li M; Wilson JM
    Hum Gene Ther; 2020 Aug; 31(15-16):808-818. PubMed ID: 32845779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience.
    Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J
    J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program.
    Chand DH; Mitchell S; Sun R; LaMarca N; Reyna SP; Sutter T
    Pediatr Neurol; 2022 Jul; 132():27-32. PubMed ID: 35605311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
    Al-Zaidy SA; Mendell JR
    Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec.
    Retson L; Tiwari N; Vaughn J; Bernes S; Adelson PD; Mansfield K; Libertini S; Kuzmiski B; Alecu I; Gabriel R; Mangum R
    Mol Ther; 2023 Oct; 31(10):2991-2998. PubMed ID: 37598295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec.
    Day JW; Finkel RS; Mercuri E; Swoboda KJ; Menier M; van Olden R; Tauscher-Wisniewski S; Mendell JR
    Mol Ther Methods Clin Dev; 2021 Jun; 21():76-82. PubMed ID: 33768131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onasemnogene Abeparvovec: First Global Approval.
    Hoy SM
    Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates.
    Mundada V; Narayan O; Arora S; Beri N; Abusamra R; Mullasery D; Parashar D
    Muscle Nerve; 2024 Oct; 70(4):808-815. PubMed ID: 39087519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    Chand D; Mohr F; McMillan H; Tukov FF; Montgomery K; Kleyn A; Sun R; Tauscher-Wisniewski S; Kaufmann P; Kullak-Ublick G
    J Hepatol; 2021 Mar; 74(3):560-566. PubMed ID: 33186633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.